Detection of BCR-ABL Fusion Gene in Chronic Myeloid Leukemia by Novel Digital PCR.
10.19746/j.cnki.issn.1009-2137.2023.06.008
- Author:
Min RUAN
1
;
Li-Li ZHANG
2
;
Ye-Mo LI
2
;
Dai-Yang LI
2
;
Zhi-Yang YUAN
2
;
Zhong-Zheng ZHENG
2
;
Qing-Shu ZENG
3
Author Information
1. Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China.
2. Shanghai Tissuebank Biotechnology Co., Ltd, Shanghai 201318, China.
3. Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China.E-mail: zengqingshu2014@163.com.
- Publication Type:Journal Article
- Keywords:
chronic myeloid leukemia;
digital polymerase chain reaction;
molecular monitoring;
side effect
- MeSH:
Humans;
Fusion Proteins, bcr-abl/genetics*;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis*;
Polymerase Chain Reaction;
Drug-Related Side Effects and Adverse Reactions;
Reverse Transcriptase Polymerase Chain Reaction
- From:
Journal of Experimental Hematology
2023;31(6):1647-1656
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To establish a new digital polymerase chain reaction (dPCR) system for the detection of BCR-ABL fusion gene in patients with chronic myeloid leukemia (CML), and explore its analytical performance and clinical applicability in the detection of BCR-ABLp190/210/230.
METHODS:A new dPCR system for detecting BCR-ABLp190/210/230 was successfully developed, and its sensitivity difference with qPCR and improvement of drug side effects in patients with CML during drug reduction or withdrawal were compared.
RESULTS:Among 176 samples, qPCR and dPCR showed high consistency in the sensitivity of detecting BCR-ABL (82.39%), and the positive rate of dPCR was about 5 times higher that of qPCR (20.45% vs 3.98%). During follow-up, blood routine (25% vs 10%), kidney/liver/stomach (25% vs 20%) and cardiac function (10% vs 0) were significantly improved after drug reduction or withdrawal in patients with initial dPCR negative compared with before drug reduction or withdrawal.
CONCLUSIONS:This new dPCR detection system can be applied to the detection of BCR-ABLp190/210/230. It has better consistency and higher positive detection rate than qPCR. Drug withdrawal or dose reduction guided by dPCR has a certain effect on improving drug side effects.
